We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
[Platelet-rich plasma made by a modified method promotes proliferation of rat osteoblast and human osteoblast in vitro].
Chinese Journal of Reparative and Reconstructive Surgery 2005 March 16
OBJECTIVE: To study the effect of serum rich in growth factors (SRGF) derived from platelet-rich plasma (PRP) on the biological function of human and rat osteoblast.
METHODS: PRP and platelet-poor plasma (PPP) obtained from healthy human and SD rat were activated by thrombin to get SRGF and serum poor in growth factors (SPGF). The level of TGF-beta1 and PDGF-AB in human-SRGF and SPGF were assayed by enzyme-linked immunoassay (ELISA). Rat and human osteoblast were cultured and identified. Rat osteoblasts were treated with 5% rat-SRGF, 5% rat-SPGF and serum-free F12 medium, respectively. And human osteoblast were treated with 5% human-SRGF, 5% human-SPGF and serum-free DMEM. Cellular mitogenic activity was evaluated by thiazolyl blue (MTT) colorimetric assay at 24, 48, 72 and 96 hours.
RESULTS: The level of TGF-beta1 in human-SRGF was 307.67 +/- 35.57 ng/ml, and that of PDGF-AB was 52.76 +/- 7.89 ng/ml. The proliferation of rat and human osteoblast were promoted after treated with rat-SRGF and human-SRGF, respectively. In rat osteoblast groups, there were significant differences in absorbency between rat-SPGF group and rat-SRGF group at 48 and 96 hours (P < 0.05). In human osteoblast groups, the differences between human-SPGF group and human-SRGF group were significant at 48, 72 and 96 hours (P < 0.05). The proliferation of these two kinds of osteoblasts almost stopped in serum-free medium, and the differences in absorbency, compared with other groups, were significant (P < 0.05).
CONCLUSION: High quality of PRP can be achieved by the improved method and SRGF is capable of up-regulating the proliferation of rat osteoblast and human osteoblast.
METHODS: PRP and platelet-poor plasma (PPP) obtained from healthy human and SD rat were activated by thrombin to get SRGF and serum poor in growth factors (SPGF). The level of TGF-beta1 and PDGF-AB in human-SRGF and SPGF were assayed by enzyme-linked immunoassay (ELISA). Rat and human osteoblast were cultured and identified. Rat osteoblasts were treated with 5% rat-SRGF, 5% rat-SPGF and serum-free F12 medium, respectively. And human osteoblast were treated with 5% human-SRGF, 5% human-SPGF and serum-free DMEM. Cellular mitogenic activity was evaluated by thiazolyl blue (MTT) colorimetric assay at 24, 48, 72 and 96 hours.
RESULTS: The level of TGF-beta1 in human-SRGF was 307.67 +/- 35.57 ng/ml, and that of PDGF-AB was 52.76 +/- 7.89 ng/ml. The proliferation of rat and human osteoblast were promoted after treated with rat-SRGF and human-SRGF, respectively. In rat osteoblast groups, there were significant differences in absorbency between rat-SPGF group and rat-SRGF group at 48 and 96 hours (P < 0.05). In human osteoblast groups, the differences between human-SPGF group and human-SRGF group were significant at 48, 72 and 96 hours (P < 0.05). The proliferation of these two kinds of osteoblasts almost stopped in serum-free medium, and the differences in absorbency, compared with other groups, were significant (P < 0.05).
CONCLUSION: High quality of PRP can be achieved by the improved method and SRGF is capable of up-regulating the proliferation of rat osteoblast and human osteoblast.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app